List of Effector Therapeutics patents

Patents where

Current Assignee

Name

Effector Therapeutics

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10112955 Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2	Patent 10112955 was granted and assigned to Effector Therapeutics on October, 2018 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	10112955	October 30, 2018
‌ US Patent 11576933 Compositions and methods for an improved antitumor immune response	Patent 11576933 was granted and assigned to Effector Therapeutics on February, 2023 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	11576933	February 14, 2023
‌ US Patent 11130757 Crystalline forms of MNK inhibitors	Patent 11130757 was granted and assigned to Effector Therapeutics on September, 2021 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	11130757	September 28, 2021
‌ US Patent 11286268 EIF4E-inhibiting compounds and methods	Patent 11286268 was granted and assigned to Effector Therapeutics on March, 2022 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	11286268	March 29, 2022
‌ US Patent 10000487 Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers	Patent 10000487 was granted and assigned to Effector Therapeutics on June, 2018 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	10000487	June 19, 2018
‌ US Patent 9669031 MNK inhibitors and methods related thereto	Patent 9669031 was granted and assigned to Effector Therapeutics on June, 2017 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	9669031	June 6, 2017
‌ US Patent 9382248 Mnk inhibitors and methods related thereto	Patent 9382248 was granted and assigned to Effector Therapeutics on July, 2016 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	9382248	July 5, 2016
‌ US Patent 9814718 MNK inhibitors and methods related thereto	Patent 9814718 was granted and assigned to Effector Therapeutics on November, 2017 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	9814718	November 14, 2017
‌ US Patent 11083727 Piperidine-substituted Mnk inhibitors and methods related thereto	Patent 11083727 was granted and assigned to Effector Therapeutics on August, 2021 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	11083727	August 10, 2021
‌ US Patent 10577378 EIF4A-inhibiting compounds and methods related thereto	Patent 10577378 was granted and assigned to Effector Therapeutics on March, 2020 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	10577378	March 3, 2020
‌ US Patent 9957277 eIF4A-inhibiting compounds and methods related thereto	Patent 9957277 was granted and assigned to Effector Therapeutics on May, 2018 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	9957277	May 1, 2018
‌ US Patent 11014926 Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2	Patent 11014926 was granted and assigned to Effector Therapeutics on May, 2021 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	11014926	May 25, 2021
‌ US Patent 10576098 Compositions and methods for treating fibrotic disease	Patent 10576098 was granted and assigned to Effector Therapeutics on March, 2020 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	10576098	March 3, 2020
‌ US Patent 10702526 Inhibitors of immune checkpoint modulators and related methods	Patent 10702526 was granted and assigned to Effector Therapeutics on July, 2020 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	10702526	July 7, 2020
‌ US Patent 9993494 Compositions and methods for treating fibrotic disease	Patent 9993494 was granted and assigned to Effector Therapeutics on June, 2018 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	9993494	June 12, 2018
‌ US Patent 11440917 EIF4A-inhibiting compounds and methods related thereto		Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	11440917	September 13, 2022
‌ US Patent 10780119 Methods and compositions for cellular immunotherapy	Patent 10780119 was granted and assigned to Effector Therapeutics on September, 2020 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	10780119	September 22, 2020
‌ US Patent 10793551 Benzimidazole-indole inhibitors of Mnk1 and Mnk2		Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	10793551	October 6, 2020
‌ US Patent 11564947 Methods and compositions for cellular immunotherapy	Patent 11564947 was granted and assigned to Effector Therapeutics on January, 2023 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	11564947	January 31, 2023
‌ US Patent 11878015 Piperidine-substituted Mnk inhibitors and methods related thereto	Patent 11878015 was granted and assigned to Effector Therapeutics on January, 2024 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	11878015	January 23, 2024
‌ US Patent 11952375 Crystalline forms of Mnk inhibitors	Patent 11952375 was granted and assigned to Effector Therapeutics on April, 2024 by the United States Patent and Trademark Office.	Effector Therapeutics	Effector Therapeutics	United States Patent and Trademark Office	11952375	April 9, 2024

21 results

0 selected

21 results

0 selected